利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

648 条记录 (耗时 0.056 秒)

    USE OF A PEPTIDE AS A THERAPEUTIC AGENT
    83.
    发明申请
    USE OF A PEPTIDE AS A THERAPEUTIC AGENT 审中-公开
    使用作为治疗剂的肽

    公开(公告)号：US20100204136A1

    公开(公告)日：2010-08-12

    申请号：US12677582

    申请日：2008-09-09

    申请人： Dorian Bevec

    发明人： Dorian Bevec

    IPC分类号： A61K38/10 ,  C07K7/08 ,  A61P35/00 ,  A61P37/00 ,  A61P29/00 ,  A61P25/00 ,  A61P11/00 ,  A61P9/00 ,  A61P3/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12

    CPC分类号： A61K38/1729 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/397 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  Y02A50/469 ,  Y02A50/49

    摘要： The present invention is directed to the use of the peptide compound Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2作为预防和/ 或治疗癌症，自身免疫性疾病，纤维化疾病，炎症性疾病，神经变性疾病，感染性疾病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp- Gly-Lys-Pro-Val-NH 2任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
    85.
    发明申请
    ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV 审中-公开
    抗性寡核苷酸靶向RSV

    公开(公告)号：US20100173980A1

    公开(公告)日：2010-07-08

    申请号：US12643578

    申请日：2009-12-21

    申请人： Andrew VAILLANT ,  Jean-Marc JUTEAU

    发明人： Andrew VAILLANT ,  Jean-Marc JUTEAU

    IPC分类号： A61K31/7088 ,  A61P31/12

    CPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/06 ,  C12N15/11 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/351 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  A61K2300/00 ,  C12N2310/3521

    摘要： Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

    摘要翻译： 描述了具有抗病毒活性的随机序列寡核苷酸及其作为抗病毒剂的用途。 在许多情况下，寡核苷酸长度大于40个核苷酸。 还描述了用于预防或治疗人或动物中的病毒感染的方法，以及用于预防人类或动物中由佐剂病毒引起的癌症的方法。 所述方法通常涉及向需要这种治疗的人或动物施用药理学上可接受的治疗有效量的至少不受序列互补作用模式作用的寡核苷酸。

    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
    89.
    发明申请
    MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS 有权
    丙型肝炎病毒大肠杆菌抑制剂

    公开(公告)号：US20100022578A1

    公开(公告)日：2010-01-28

    申请号：US12441812

    申请日：2007-11-16

    申请人： Pierre Jean-Marie Raboisson ,  Herman Augustinus De Kock ,  David Craig Mc Gowan ,  Wim Van De Vreken ,  Abdellah Tahri ,  Sandrine Marie Helene Vendeville

    发明人： Pierre Jean-Marie Raboisson ,  Herman Augustinus De Kock ,  David Craig Mc Gowan ,  Wim Van De Vreken ,  Abdellah Tahri ,  Sandrine Marie Helene Vendeville

    IPC分类号： A61K31/4709 ,  C07D245/04 ,  A61K31/4741 ,  A61P31/12

    CPC分类号： C07D491/056 ,  A61K31/427 ,  A61K31/4741 ,  C07D401/12 ,  C07D491/04 ,  C07D491/048 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  A61K2300/00

    摘要： Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein each dashed line (represented by represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 is C1-6alkyl or C3-7cycloalkyl; R5 is hydrogen, halo, C1-6alkyl, hydroxy, C1-6alkoxy, polyhaloC1-6alkyl; R6 is hydrogen, C1-6alkoxy, mono- or diC1-6alkylamino; or R5 and R6 may form a 5- or 6-membered unsaturated or partially unsaturated ring, optionally comprising one or two selected from O, N and S; R7 is hydrogen; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl; R8 is C3-7cycloalkyl optionally substituted with C1-6alkyl; C1-6alkyl optionally substituted with C3-7cycloalkyl; or —NR8aR8b; R8a and R8b are C1-6alkyl, or both may form a 5- or 6-membered saturated heterocyclic ring; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).

    摘要翻译： 式（I）的HCV复制抑制剂及其盐和立体异构体，其中每个虚线（由表示可选的双键; X是N，CH，其中X具有双键，它是C; R1是-OR7， -NH-SO 2 R 8; R 2是氢，并且其中X是C或CH，R 2也可以是C 1-6烷基; R 3是氢，C 1-6烷基，C 1-6烷氧基C 1-6烷基，C 3-7环烷基; n是3,4,5 或6; R 4是C 1-6烷基或C 3-7环烷基; R 5是氢，卤素，C 1-6烷基，羟基，C 1-6烷氧基，多卤代C 1-6烷基; R 6是氢，C 1-6烷氧基，单或二C 1-6烷基氨基;或 R 5和R 6可以形成5-或6-元不饱和或部分不饱和的环，任选地包含一个或两个选自O，N和S; R 7是氢;任选地被C 1-6烷基取代的C 3-7环烷基; 被C 3-7环烷基取代; R 8是任选取代的C 3-7环烷基 取代C 1-6烷基; 任选被C 3-7环烷基取代的C 1-6烷基; 或-NR8aR8b; R8a和R8b是C1-6烷基，或两者可以形成5或6元饱和杂环; 含有化合物（I）的药物组合物和制备化合物（I）的方法。